727 related articles for article (PubMed ID: 9406695)
1. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
2. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Herskovic T; Hanley D; Markowitz A; Dunn R; Siegel J; Kamal T; Goldenberg DM
J Clin Oncol; 1996 Apr; 14(4):1209-17. PubMed ID: 8648376
[TBL] [Abstract][Full Text] [Related]
3. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical site of tumour manifestation?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Becker H; Becker W
Eur J Nucl Med; 1997 Feb; 24(2):184-91. PubMed ID: 9021116
[TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and somatostatin analogues in medullary thyroid carcinoma.
O'Byrne KJ; O'Hare N; Sweeney E; Freyne PJ; Cullen MJ
Nucl Med Commun; 1996 Sep; 17(9):810-6. PubMed ID: 8895910
[TBL] [Abstract][Full Text] [Related]
7. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.
Arslan N; Ilgan S; Yuksel D; Serdengecti M; Bulakbasi N; Ugur O; Ozguven MA
Clin Nucl Med; 2001 Aug; 26(8):683-8. PubMed ID: 11452174
[TBL] [Abstract][Full Text] [Related]
8. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
9. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
11. Metabolic and receptor imaging of metastatic medullary thyroid cancer: does anti-CEA and somatostatin-receptor scintigraphy allow for prognostic predictions?
Behr TM; Becker W
Eur J Nucl Med; 1999 Jan; 26(1):70-1. PubMed ID: 10048954
[No Abstract] [Full Text] [Related]
12. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
13. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
[TBL] [Abstract][Full Text] [Related]
14. Improved selection of patients for reoperation for medullary thyroid cancer by imaging with radiolabeled anticarcinoembryonic antigen antibodies.
Juweid M; Sharkey RM; Swayne LC; Goldenberg DM
Surgery; 1997 Dec; 122(6):1156-65. PubMed ID: 9426433
[TBL] [Abstract][Full Text] [Related]
15. Functional nuclear medicine imaging of medullary thyroid cancer.
Bozkurt MF; Uğur O; Banti E; Grassetto G; Rubello D
Nucl Med Commun; 2008 Nov; 29(11):934-42. PubMed ID: 18836370
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
17. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid.
Krausz Y; Rosler A; Guttmann H; Ish-Shalom S; Shibley N; Chisin R; Glaser B
Clin Nucl Med; 1999 Apr; 24(4):256-60. PubMed ID: 10466522
[TBL] [Abstract][Full Text] [Related]
19.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
20. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
